<DOC>
	<DOCNO>NCT02355379</DOCNO>
	<brief_summary>Colorectal cancer occur mainly elderly patient . Recent estimation show France 50 % patient diagnosed colorectal cancer 70 year old . Adjuvant chemotherapy demonstrate benefit disease-free survival overall survival stage III colon cancer resection . Nevertheless adjuvant chemotherapy poorly use elderly patient . Prognostic improvement chemotherapy base 5FU suggested post-hoc analysis randomize prospective clinical trial . But elderly patient study highly select patient old 80 represent 0.7 % total population . Thus , still concern benefit adjuvant 5FU-based chemotherapy elderly unselected patient . The recommended treatment stage III adjuvant chemotherapy combination fuoropyrimidine oxaliplatin . Nevertheless oxaliplatin demonstrate survival advantage elderly patient . Altogether still two matter debate : - First , benefit fluoropyrimidine-based adjuvant chemotherapy unfit elderly patient ? - Second , benefit oxaliplatin-based adjuvant chemotherapy fit elderly patient ? The aim randomize phase III study evaluate benefit disease-free survival adjuvant chemotherapy elderly patient chemotherapy . The elderly patient population dichotomize two group accord physician 's choice multidisciplinary evaluation involve geriatrician , two different randomization assignment . The patient expect life-expectancy 4 year accord Lee score exclude study . Some biological tumour abnormality frequently observe elderly ( i.e . mismatch repair deficiency ) , therefore evaluation specific biological prognostic factor need elderly population .</brief_summary>
	<brief_title>Randomised Study Evaluating Adjuvant Chemotherapy After Resection Stage III Colonic Adenocarcinoma Patients 70 Over</brief_title>
	<detailed_description>Colorectal cancer occur mainly elderly patient . Recent estimation show France 50 % patient diagnosed colorectal cancer 70 year old . Adjuvant chemotherapy demonstrate benefit disease-free survival overall survival stage III colon cancer resection . Nevertheless adjuvant chemotherapy poorly use elderly patient . Prognostic improvement chemotherapy base 5FU suggested post-hoc analysis randomize prospective clinical trial . But elderly patient study highly select patient old 80 represent 0.7 % total population . Thus , still concern benefit adjuvant 5FU-based chemotherapy elderly unselected patient . The recommended treatment stage III adjuvant chemotherapy combination fuoropyrimidine oxaliplatin . Nevertheless oxaliplatin demonstrate survival advantage elderly patient . Altogether still two matter debate : - First , benefit fluoropyrimidine-based adjuvant chemotherapy unfit elderly patient ? - Second , benefit oxaliplatin-based adjuvant chemotherapy fit elderly patient ? The aim randomize phase III study evaluate benefit disease-free survival adjuvant chemotherapy elderly patient chemotherapy . The elderly patient population dichotomize two group accord physician 's choice multidisciplinary evaluation involve geriatrician , two different randomization assignment . The patient expect life-expectancy 4 year accord Lee score exclude study . Some biological tumour abnormality frequently observe elderly ( i.e . mismatch repair deficiency ) , therefore evaluation specific biological prognostic factor need elderly population .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Age â‰¥ 70 year Patient consider able receive chemotherapy Lee score detail faxed CRGA Stage III colon adenocarcinoma R0 resection primary tumor Start potential adjuvant chemotherapy within 12 week surgery No prior chemotherapy colon cancer Geriatric Selfadministered questionnaire complete faxed CRGA Geriatric Questionnaire complete team fax CRGA Effective contraception men patient throughout treatment least 6 month discontinuation oxaliplatin Consent sign Other progressive disease ( cancer uncontrolled less 2 year ) Rectal Cancer ( locate less 15 cm anal verge endoscopy subperitoneal ) ANC &lt; 2000 / mm3 group 1 ANC &lt; 1500 / mm3 group 2 platelet &lt; 100,000 / mm3 hemoglobin &lt; 9 g / dL Neuropathy patient group 1 Known deficit dihydropyrimidine dehydrogenase ( DPD ) Patients severe hepatic insufficiency Any contrindication drug use study Inability submit medical followup geographical , social psychological reason .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Adjuvant chemotherapy colonic adenocarcinoma elderly</keyword>
</DOC>